Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Olmesartan Improves Insulin Resistance in Chronic Kidney Disease Patients: Presented at ASN By Maria Bishop PHILADELPHIA, PA -- November 15, 2005 -- Olmesartan, an angiotensin receptor blocker, has been demonstrated to improve the insulin resistance and metabolic syndrome prevalent in patients with chronic kidney disease. Researchers reported the findings here on November 12th at the 38th Annual Meeting and Scientific Exposition of the American Society of Nephrology (ASN). Researchers led by José Luño, MD, Nephrology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain, administered olmesartan at a 40-mg dose for 16 weeks to 52 patients with stages 3 and 4 chronic kidney disease (mean estimated glomerular filtration rate of 42.17 mL/min.). Treatment resulted in a number of significant decreases, Dr. Luño noted. Among those decreases observed were the following: · blood pressure (158/84 mm Hg before treatment versus 137/74 mm Hg after treatment; P = .000) · urinary protein excretion (2.29 versus 1.21; P = .03) · homeostasis model assessment index (6 versus 4.7 mcU/mL x mmol/L; P = .02) · plasma glucose (99 versus 92 mg/dL; P = .000) · plasma insulin (23.1 versus 20.9 UI/mL; P = .05) and · glycated haemoglobin (5.33% versus 4.85%; P = .002). Some inflammatory parameters were also reduced with olmesartan treatment, including fibrinogen, C-reactive protein and interleukin-6. There were no significant differences in body mass index, triglycerides, or cholesterol (either high-density lipoprotein or low-density lipoprotein cholesterol) after olmesartan treatment. Study participants were nondiabetic and were never treated previously with renin-angiotensin-system blocking drugs. Baseline data were compared with data obtained from 25 healthy individuals of similar age (approximately 70 years old) and normal renal function (98.33 mL/min), who served as a control group. Compared with controls, patients with chronic kidney disease presented at baseline with significantly higher blood pressure, as well as higher triglyceride levels and lower high-density lipoprotein levels, higher insulin levels and a higher mean homeostasis model assessment index. The prevalence of metabolic syndrome in the patients with chronic kidney disease was 44% at baseline. [Presentation title: Olmesartan Improves Insulin Resistance in Chronic Kidney Disease Patients. Abstract 960] E-mail this page to a friend or colleague! To print, use this version